Peregrine Plummets After Unreliable Lung Cancer Results

Peregrine Pharmaceuticals Inc. plunged the most ever after the biotechnology company said the survival rates from its lung cancer study reported earlier this month were unreliable.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.